California Cancer Associates for Research and Excellence

Encinitas, California 92024

1 studies enrolling now · 13 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer, Colorectal Adenocarcinoma, Diffuse Large B Cell Lymphoma, Esophageal Cancer, Head and Neck Cancer, Malignancies, Melanoma, Metastatic Castration-resistant Prostate Cancer, Metastatic Solid Tumor

Studies at this site

• JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Running, not enrolling
• Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) — Withdrawn before enrolling
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma — Stopped early
• Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer — Completed
• A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer — Completed
• Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers — Completed
• PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL — Completed
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma — Completed
• Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer — Completed
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients — Completed
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects — Completed
• Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma — Status unconfirmed